(179)fabricated tri-specific NK cell engagers based on PLGA nanoparticles, successfully combining NK cells with tumor cells to activate NK cells against EGFR-positive colorectal adenocarcinoma, triple-negative breast cancer, epidermoid cancer, and melanoma, respectively. The gene discussed is EGFR; the disease is neoplasm.